• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Virol J . Immune evasion, infectivity, and membrane fusion of the SARS-CoV-2 JN.1 variant

tetano

Editor, Senior Moderator
Virol J


. 2025 May 24;22(1):162.
doi: 10.1186/s12985-025-02737-3. Immune evasion, infectivity, and membrane fusion of the SARS-CoV-2 JN.1 variant

Haijun Tang[SUP] #[/SUP][SUP] 1 2 [/SUP], Yanhang Zhuo[SUP] #[/SUP][SUP] 1 2 [/SUP], Jianlin Chen[SUP] #[/SUP][SUP] 1 3 [/SUP], Rongzhao Zhang[SUP] #[/SUP][SUP] 1 2 [/SUP], Miao Zheng[SUP] 4 [/SUP], Xinghua Huang[SUP] 1 2 [/SUP], Yisheng Chen[SUP] 1 2 [/SUP], Minjian Huang[SUP] 1 2 [/SUP], Zhaonan Zeng[SUP] 1 2 [/SUP], Xueping Huang[SUP] 5 6 [/SUP], Chenfeng Han[SUP] 7 [/SUP], Yi Huang[SUP] 8 9 10 11 12 [/SUP]



Affiliations
Abstract

SARS-CoV-2 undergoes continuous mutations during transmission, resulting in a variety of Omicron subvariants. Currently, SARS-CoV-2 BA.2.86 and its descendants JN.1, KP.2, KP.1.1 have been identified as the primary variants spreading globally. These emerging Omicron variants have increased transmissibility, potentially elevating the risk of viral reinfection in the population. However, the biological characteristics of newly-emerged Omicron subvariants in infecting host cells remain unclear. In this study, we assessed the neutralization effect of BA.2.86 and its descendant JN.1, as well as D614G, BA.2, BA.4/5, XBB.1.5, EG.5.1, HV.1, HK.3, JD.1.1 and JG.3 on convalescent sera obtained from individuals infected with BA.5 or XBB.1.5 strain. We evaluated the biological characteristics of variants spike proteins by measuring viral infectivity, affinity for receptors, and membrane fusion. Compared to XBB-related subvariants, BA.2.86 exhibited a diminished immune escape response, but JN.1 displayed a markedly augmented immune escape capability, which was closely related to its rapid transmission. BA.2.86 was less infectious in susceptible cells, while the JN.1 variant exhibited relatively high infectivity. Notably, BA.2.86 and JN.1 exhibited low fusion activity in 293 T-ACE2 cells, but relatively high fusogenicity in transmembrane protease serine 2 (TMPRSS2) overexpression cells. This study explored the evolutionary characteristics of emerging Omicron subvariants in host adaptation, and provided new strategies for the prevention and treatment of coronavirus disease 2019 (COVID-19).

Keywords: Immune escape; Infectivity; JN.1; Omicron subvariant.

 
Back
Top Bottom